SUPRIYAPharmaceuticals
Supriya Lifescience Ltd — Cash Flow Statement
₹561.90
-1.58%
Supriya Lifescience Ltd Cash Flow Statement (Annual)
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Free Cash Flow | 2.30 Cr | -32.35 Cr | -44.30 Cr | -11.10 Cr | — |
| Capital Expenditure | -162.38 Cr | -145.66 Cr | -107.91 Cr | -59.90 Cr | — |
| End Cash Position | 79.15 Cr | 74.96 Cr | 157.58 Cr | 227.91 Cr | — |
| Beginning Cash Position | 74.96 Cr | 157.58 Cr | 227.91 Cr | 89.28 Cr | — |
| Financing Cash Flow | -8.23 Cr | -22.36 Cr | -10.28 Cr | 149.65 Cr | — |
| Interest Paid Cff | -1.69 Cr | -0.55 Cr | -0.50 Cr | -3.66 Cr | — |
| Cash Dividends Paid | -6.44 Cr | -4.83 Cr | -4.83 Cr | -4.39 Cr | — |
| Net Issuance Payments Of Debt | 0.00 | -16.63 Cr | -4.67 Cr | -48.61 Cr | — |
| Net Short Term Debt Issuance | 0.00 | -16.63 Cr | -4.67 Cr | -48.61 Cr | — |
| Net Long Term Debt Issuance | 0.00 | 0.00 | 0.00 | 0.00 | — |
| Investing Cash Flow | -152.24 Cr | -173.57 Cr | -123.65 Cr | -59.82 Cr | — |
| Interest Received Cfi | 9.57 Cr | 10.57 Cr | 9.49 Cr | — | — |
| Dividends Received Cfi | 50000.00 | 50000.00 | 50000.00 | — | — |
| Net Investment Purchase And Sale | 0.56 Cr | -38.50 Cr | -25.24 Cr | 0.00 | — |
| Net PPE Purchase And Sale | -162.38 Cr | -145.66 Cr | -107.91 Cr | -59.82 Cr | — |
| Purchase Of PPE | -162.38 Cr | -145.66 Cr | -107.91 Cr | -59.90 Cr | — |
| Operating Cash Flow | 164.68 Cr | 113.31 Cr | 63.60 Cr | 48.80 Cr | — |
| Taxes Refund Paid | -59.18 Cr | -37.65 Cr | -30.68 Cr | -60.96 Cr | — |
| Change In Working Capital | -38.36 Cr | -17.14 Cr | -33.81 Cr | -104.35 Cr | — |
| Change In Other Current Liabilities | -8.04 Cr | 2.75 Cr | -14.46 Cr | -6.71 Cr | — |
| Change In Other Current Assets | 10.51 Cr | -18.60 Cr | -41.70 Cr | -31.74 Cr | — |
| Change In Payable | 14.98 Cr | -4.66 Cr | 15.26 Cr | -2.05 Cr | — |
| Change In Inventory | -33.10 Cr | 30.52 Cr | -23.46 Cr | -19.83 Cr | — |
| Change In Receivables | -22.71 Cr | -27.16 Cr | 30.55 Cr | -44.74 Cr | — |
| Other Non Cash Items | -7.88 Cr | -10.03 Cr | -8.99 Cr | -3.25 Cr | — |
| Depreciation And Amortization | 20.44 Cr | 15.81 Cr | 11.81 Cr | 10.12 Cr | — |
| Depreciation | 20.44 Cr | 15.81 Cr | 11.81 Cr | 10.12 Cr | — |
| Pension And Employee Benefit Expense | 1.18 Cr | -3.37 Cr | 1.69 Cr | — | 0.00 |
| Gain Loss On Investment Securities | -50000.00 | -50000.00 | -50000.00 | — | — |
| Gain Loss On Sale Of PPE | 60000.00 | 0.00 | 0.11 Cr | — | 0.00 |
| Net Income From Continuing Operations | 248.48 Cr | 165.69 Cr | 123.49 Cr | 207.25 Cr | — |
| Changes In Cash | 4.20 Cr | -82.63 Cr | -70.33 Cr | 138.63 Cr | — |
| Issuance Of Capital Stock | — | 0.00 | 0.00 | 200.00 Cr | — |
| Other Cash Adjustment Outside Changein Cash | — | 10000.00 | -10000.00 | — | -10000.00 |
| Net Common Stock Issuance | — | 0.00 | 0.00 | 200.00 Cr | — |
| Common Stock Issuance | — | 0.00 | 0.00 | 200.00 Cr | — |
| Net Other Investing Changes | — | 10000.00 | -10000.00 | — | 10000.00 |
| Net Other Financing Charges | — | — | 9.49 Cr | 7.07 Cr | 4.98 Cr |
| Sale Of PPE | — | — | 0.54 Cr | 0.08 Cr | 1.44 Cr |
| Interest Paid Cfo | — | — | — | -0.34 Cr | -0.45 Cr |
| Provisionand Write Offof Assets | — | — | — | 0.00 | 0.00 |
All figures in ₹ Crores. Source: NSE/BSE filings via Bull Run.
More on Supriya Lifescience Ltd
Data from NSE/BSE public filings. Educational purposes only. Bull Run is not SEBI-registered. Not investment advice.